{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:13:50Z","timestamp":1780582430246,"version":"3.54.1"},"reference-count":13,"publisher":"SLACK, Inc.","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatric Annals"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:p>\n            There is evidence that doxazosin is effective in the treatment of posttraumatic stress disorder (PTSD). Doxazosin is a \u201cme-too\u201d drug of prazosin. Doxazosin has an improved absorption profile and this likely minimizes the risk for unintended adverse hypotensive effects. The availability of doxazosin in the gastrointestinal therapeutic system (GITS) form permits a higher initial daily dose (4 mg\/day) while avoiding significant first-dose side effects. The treatment of PTSD with prazosin has several disadvantages due to its short duration of action (6\u20138 hours), which results in multiple doses being required. Prazosin may wear off and this may lead to nightmares in the latter half of the sleep. Doxazosin has significant advantages over prazosin in clinical practice because it has a long half-life and requires only once-daily dosing. This may lead to better adherence and greater effectiveness in the treatment of PTSD.\n            <jats:bold>\n              [\n              <jats:italic>Psychiatr Ann<\/jats:italic>\n              . 2016;46(9):553\u2013555.]\n            <\/jats:bold>\n          <\/jats:p>","DOI":"10.3928\/00485713-20160728-01","type":"journal-article","created":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T17:57:11Z","timestamp":1473357431000},"page":"553-555","source":"Crossref","is-referenced-by-count":19,"title":["Evidence for Using Doxazosin in the Treatment of Posttraumatic Stress Disorder"],"prefix":"10.3928","volume":"46","author":[{"given":"Cherish","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maju Mathew","family":"Koola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"issue":"4","key":"e_1_3_1_2_2","article-title":"Naltrexone and prazosin combination for posttraumatic stress disorder and alcohol use disorder","volume":"16","author":"Qazi H","year":"2014","journal-title":"Prim Care Companion CNS Disord"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.14l01676"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00067.x"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.12l01356"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181c827ae"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09681"},{"key":"e_1_3_1_8_2","article-title":"Doxazosin, an alpha-1-adrenergic-receptor antagonist, for nightmares in patients with posttraumatic stress disorder and\/or borderline personality disorder: a chart review","author":"Roepke S","year":"2016","journal-title":"Pharmacopsychiatry"},{"key":"e_1_3_1_9_2","unstructured":"Raskind MA Peskind ER Chow B et al. A multicenter trial of prazosin for combat posttraumatic stress disorder with trauma nightmares: VA Cooperative Study No. 563. N Engl J Med . In press. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00532493. Accessed August 8 2016."},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045125313500982"},{"key":"e_1_3_1_11_2","unstructured":"Furmaga E Geraci M Semla T. Alpha-blocker combination therapy in PTSD and BPH. Recommendations for use. June 2012. VA Pharmacy Benefits Management Services Medical Advisory Panel and VISN Pharmacist Executives. http:\/\/www.pbm.gov. Accessed August 30 2016."},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1051"},{"key":"e_1_3_1_13_2","volume-title":"Cardura (doxazosin) [package insert]","year":"2009"},{"key":"e_1_3_1_14_2","volume-title":"Minipress (prazosin) [package insert]","year":"2009"}],"container-title":["Psychiatric Annals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/psychiatry\/journals\/psycann\/2016-9-46-9\/%7B8aaff22c-0240-4eed-9802-608cf374d462%7D\/evidence-for-using-doxazosin-in-the-treatment-of-posttraumatic-stress-disorder","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T09:04:15Z","timestamp":1683104655000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/00485713-20160728-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.3928\/00485713-20160728-01"],"URL":"https:\/\/doi.org\/10.3928\/00485713-20160728-01","relation":{},"ISSN":["0048-5713","1938-2456"],"issn-type":[{"value":"0048-5713","type":"print"},{"value":"1938-2456","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}